Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
June-2021 Volume 21 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
June-2021 Volume 21 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Comparison of anti‑inflammatory effects of Mecasin and its constituents on lipopolysaccharide‑stimulated BV2 cells

  • Authors:
    • Tingting Wang
    • Wonmin Ko
    • Joon-Yeong Shin
    • Dongho Choi
    • Dong-Sung Lee
    • Sungchul Kim
  • View Affiliations / Copyright

    Affiliations: ALS/MND Center of Wonkwang University Gwangju Korean Medicine Hospital, Gwangju 61729, Republic of Korea, Department of Pharmacy, Chosun University, Dong‑gu, Gwangju 61452, Republic of Korea, Professional Graduate School, Wonkwang University, Jeonbuk, Iksan 54538, Republic of Korea
    Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Article Number: 591
    |
    Published online on: April 8, 2021
       https://doi.org/10.3892/etm.2021.10023
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Mecasin, a traditional medicine, contains nine herbal constituents: Curcuma longa, Salvia miltio rhiza, Gastrodia elata, Chaenomeles sinensis, Polygala tenuifolia, Paeonia japonica, Glycyrrhiza uralensis, Atractylodes japonica and processed Aconitum carmichaeli. Several biological effects of mecasin have been described both in vivo and in vitro. Previous studies have demonstrated that mecasin has anti‑inflammatory effects. The purpose of the present study was to determine anti‑inflammatory effects of mecasin and its natural product constituents on lipopolysaccharide (LPS)‑stimulated BV2 cells by measuring nitrite and nitric oxide contents. Nitrite production levels in LPS‑stimulated BV2 cells incubated with mecasin and each individual constituent of mecasin were measured. The results suggested that C. longa, P. tenuifolia and P. japonica inhibited nitrite production in a pattern similar to that of mecasin. The effect of mecasin was likely a result of synergistic effects of its natural herb constituents.

Introduction

Microglia are widely distributed in the brain and spinal cord. Immune abnormalities occurring in degenerative diseases of the central nervous system are mainly characterized by excessive activation of microglia and elevated levels of inflammatory factors in specific brain regions (1). Excessive activation and proliferation of microglia in numerous neurodegenerative diseases are important manifestations of inflammatory responses of central nervous system diseases such as Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, cerebellar atrophy and multiple sclerosis. According to previous studies, excessive activation of microglia and continuous releases of nitric oxide (NO), inducible NO synthase (iNOS), interleukin-1β (IL-1β) and other pro-inflammatory factors are causes of neuronal cell death (2-4). These inflammatory factors have strong toxic effects on neurons, ultimately leading to degeneration and necrosis. Therefore, inhibiting microglia hyperactivation is currently an important strategy for treating neurological diseases. Microglia may be activated by lipopolysaccharide (LPS), interferon-γ and β-amyloid, resulting in the production of inflammatory cell mediators.

Mecasin (KCHO-1, Gamijakyakgamchobuja-tang), has anti-inflammatory and antioxidant properties. It is composed of Curcuma longa, Salvia miltiorrhiza, Gastrodia elata, Chaenomeles sinensis, Polygala tenuifolia, Paeonia japonica, Glycyrrhiza uralensis, Atractylodes japonica and processed Aconitum carmichaeli (5,6). Through continuous research in recent years, various medical effects of mecasin have been discovered. For instance, it was demonstrated to have a role in reducing pain, the regeneration of gamma-aminobutyric acid neurons and NO reduction in neuropathic pain of rats (5). It also has anti-seizure, analgesic, antipyretic, anti-inflammatory, anti-ulcer, osteoarthritis-suppressing, neuro-protective and anti-neuroinflammatory effects. Its safety has also been demonstrated in both in vitro and in vivo trials (7-15).

Previous studies have indicated that mecasin acts by inducing heme oxygenase 1 expression and suppressing nuclear factor κB (NF-κB)-mediated production of proinflammatory mediators, cytokines and proteins in LPS-stimulated microglia (10). However, the contribution of each herbal medicine constituent to the effect of mecasin has remained elusive. Therefore, the objective of the present study was to determine whether constituents of mecasin may have synergistic anti-neuroinflammatory effects using LPS-stimulated BV2 cells.

Materials and methods

Materials

Tissue culture reagents such as RPMI 1640 and fetal bovine serum (FBS) were purchased from Gibco (Thermo Fisher Scientific, Inc.). All chemicals were obtained from Sigma-Aldrich (Merck KGaA). Primary antibodies including anti-cyclooxygenase (COX)-2 (cat. no. SC-376861), anti-iNOS (cat. no. SC-7271) and anti-β-actin (cat. no. SC-47778) were purchased from Santa Cruz Biotechnology, Inc. Anti-rabbit (cat. no. AP132P) and anti-mouse (cat. no. AP124P) secondary antibodies were purchased from EMD Millipore.

Cell culture and cell viability assay

BV2 microglia were donated by Youn-Chul Kim, Wonkwang University (Iksan, Korea). BV2 microglia were seeded at 5x105 cells/ml in RPMI 1640 supplemented with 10% heat-inactivated FBS, penicillin G (100 units/ml), streptomycin (100 mg/ml), and L-glutamine (2 mM) and incubated at 37˚C in a humidified atmosphere containing 5% CO2. For the determination of cell viability, 50 mg/ml of MTT was added to 0.1 ml of each well (1x105 cells/ml in 96-well plates) for 4 h. The resulting formazan was dissolved in DMSO, after which the optical density of the solution was measured at 540 nm using an ELISA microplate reader (Model 550; Bio-Rad Laboratories Inc.). The optical density of the formazan solution from control (untreated) cells was considered to represent 100% viability.

Proportions and concentrations of individual ingredients of mecasin

Mecasin and its herbal medicine constituents were obtained from Hanpoong Pharm & Foods. The concentration of the individual ingredients was determined based on concentrations of mecasin at 25, 50, 100 and 200 µg/ml (Table I).

Table I

Composition of mecasin and proportions of its constituents.

Table I

Composition of mecasin and proportions of its constituents.

Individual ingredientRatio (%)Treatment concentration by ratio of mecasin concentration (µg/ml)
Curcuma longa17.44.35, 8.7, 17.4, 34.8
Salvia miltiorrhiza17.44.35, 8.7, 17.4, 34.8
Gastrodia elata17.44.35, 8.7, 17.4, 34.8
Chaenomeles sinensis8.72.17, 4.35, 8.7, 17.4
Polygala tenuifolia8.72.17, 4.35, 8.7, 17.4
Paeonia japonica8.72.17, 4.35, 8.7, 17.4
Glycyrrhiza uralensis8.72.17, 4.35, 8.7, 17.4
Atractylodes japonica8.72.17, 4.35, 8.7, 17.4
Processed Aconitum carmichaeli4.351.09, 2.17, 4.35, 8.7
Nitrite assay

BV2 microglia were cultured in 48-well plates at a density of 5x105 cells/well (100 µl) for 12 h. Subsequently, the cells were pre-treated with indicated concentrations of each test sample for 3 h and then stimulated with LPS at 1 µg/ml for 24 h. The amount of NO released from cells into the medium was then measured using Griess reagent [0.1% wv N-(1-naphathyl)-ethylenediamine and 1% (wv) sulfanilamide in 5% (vv) phosphoric acid]. The absorbance of each well was then measured at 570 nm using an ELISA microplate reader (Model 550; Bio-Rad Laboratories Inc.). NO was quantified using a standard curve.

Western blotting analysis

The pelleted BV2 microglia were washed with PBS, and then lysed using RIPA buffer (Thermo Fisher Scientific, Inc.; cat. no. 89900). Equal quantities of proteins (30 µg) were quantified using Protein Assay Dye Reagent Concentrate obtained from Bio-Rad Laboratories, mixed in the sample loading buffer and separated by 7.5% SDS-PAGE. Separated proteins were transferred to a nitrocellulose membrane. Non-specific binding to the membrane was blocked by incubating with a solution of 5% skimmed milk at 37˚C for 1 h. The membrane was incubated with primary antibodies including COX-2 (1:1,000), iNOS (1:1,000) and β-actin (1:1,000) at 4˚C overnight, and then reacted with horseradish peroxidase-conjugated rabbit (goat anti-rabbit IgG; 1:5,000) and mouse (goat anti-mouse IgG; 1:5,000) secondary antibodies at 37˚C for 1 h, followed by ECL detection (GENDEPOT Laboartories; cat. no. W3652-020). Quantitative densitometric analysis was conducted using ImageJ software 1.47v (National Institutes of Health).

Statistical analysis

Quantitative data are expressed as the mean ± standard deviation of at least three independent experiments. To compare among three groups, one-way analysis of variance was used followed by Dunnett's test. All statistical analyses were performed using GraphPad Prism software, version 5.01 (GraphPad Software Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results

Comparison of cell viability

Cytotoxicity was measured using the MTT assay. The results indicated that C. longa and G. elata were cytotoxic at a concentration of 100 µg/ml or higher, while P. tenuifolia and P. japonica were cytotoxic at a concentration of 200 µg/ml or higher. No toxicity was observed for mecasin at concentrations of ≤200 µg/ml and the maximum concentration used in the present study was within the concentration range that caused no toxicity (Fig. 1, Fig. 2, Fig. 3).

Figure 1

Comparison of cell viability after treatment with mecasin, Curcuma longa, Salvia miltiorrhiza and Gastrodia elata. BV2 cells were incubated with each sample at indicated concentrations for 24 h. Cell viability was determined using an MTT assay. Values are expressed as the mean ± standard deviation of three independent experiments. ***P<0.001 compared to the control (untreated group).

Figure 2

Comparison of cell viability after treatment with mecasin, Chaenomeles sinensis, Polygala tenuifolia and Paeonia japonica. BV2 cells were incubated with test sample at indicated concentrations for 24 h. Cell viability was determined using an MTT assay. Values are expressed as the mean ± standard deviation of three independent experiments. ***P<0.001 compared to the control (untreated group).

Figure 3

Comparison of cell viability after treatment with mecasin, Glycyrrhiza uralensis, Atractylodes japonica and processed Aconitum carmichaeli. BV2 cells were incubated with test sample at indicated concentrations for 24 h. Cell viability was determined using an MTT assay. Values are expressed as the mean ± standard deviation of three independent experiments.

Inhibition rate of nitrite production

BV2 cells were pre-treated with each test sample at the indicated concentrations for 3 h and then stimulated with LPS at 1 µg/ml for 24 h. The concentration of individual ingredients was set based on concentrations of mecasin at 25, 50, 100 and 200 µg/ml (Table I). The inhibition rate of nitrite production was compared after this concentration was set. Mecasin at 25, 50, 100 and 200 µg/ml contained C. longa at 4.35, 8.7, 17.4 and 34.8 µg/ml, respectively. For mecasin, the inhibition rate of nitrite production was 14.5% at 25 µg/ml, 38.8% at 50 µg/ml, 61.2% at 100 µg/ml and 88.0% at 200 µg/ml. For C. longa, which had the greatest inhibitory effects on nitrite production among individual constituents, the inhibition rate of nitrite production was 4.2% at 4.35 µg/ml, 21.1% at 8.7 µg/ml, 34.8% at 17.4 µg/ml and 71.9% at 34.8 µg/ml. When inhibition rates of nitrite generation were compared, mecasin had a higher rate than its individual constituents. Its inhibition effect on nitrite production was dose-dependent. Among its ingredients, C. longa had the highest inhibition rate, followed by P. tenuifolia and P. japonica. The remaining six individual herbal components did not exert any significant inhibition on nitrite production (Table II; Fig. 4, Fig. 5, Fig. 6) .

Figure 4

Effects of mecasin, Curcuma longa, Salvia miltiorrhiza and Gastrodia elata on nitrite production. Cells were pretreated with test sample at indicated concentrations for 3 h and stimulated with LPS at 1 µg/ml for 24 h. The nitrite concentration was determined as described in the nitrate assay paragraph of the Materials and methods. Values are expressed as the mean ± standard deviation of three independent experiments. ***P<0.001 vs. LPS group. The control is the untreated group. LPS, lipopolysaccharide.

Figure 5

Effects of mecasin, Chanomeles sinensis, Polygala tenuifolia and Paeonia japonica on nitrite production. Cells were pretreated with test sample at the indicated concentration for 3 h and stimulated with LPS at 1 µg/ml for 24 h. The nitrite concentration was determined as described in the nitrate assay paragraph of the Materials and methods. Values are expressed as the mean ± standard deviation of three independent experiments. *P<0.05 and ***P<0.001 vs. LPS group. The control is the untreated group. LPS, lipopolysaccharide.

Figure 6

Effects of mecasin, Glycyrrhiza uralensis, Atractylodes japonica and processed Aconitum carmichaeli on nitrite production. Cells were pretreated with test sample at the indicated concentrations for 3 h and stimulated with LPS at 1 µg/ml for 24 h. The nitrite concentration was determined as described in the nitrate assay paragraph of the Materials and methods. Values are expressed as the mean ± standard deviation of three independent experiments. *P<0.05 and ***P<0.001 vs. LPS group. The control is the untreated group. LPS, lipopolysaccharide.

Table II

Nitrite inhibition percentages of mecasin and its constituents.

Table II

Nitrite inhibition percentages of mecasin and its constituents.

 Nitrite inhibition (%)
ItemConcentration 1Concentration 2Concentration 3Concentration 4
Mecasin14.538.861.288.0
Curcuma longa4.221.134.871.9
Salvia miltiorrhiza3.012.112.619.8
Gastrodia elata11.98.81.311.4
Chaenomeles sinensis13.315.219.621.0
Polygala tenuifolia5.05.427.738.8
Paeonia japonica1.418.034.728.4
Glycyrrhiza uralensis10.417.14.814.0
Atractylodes japonica2.49.516.218.4
Processed Aconitum carmichaeli6.76.217.816.9

[i] Concentration 1 [mecasin (25 µg/ml)]: Curcuma longa (4.35 µg/ml), Salvia miltiorrhiza (4.35 µg/ml), Gastrodia elata (4.35 µg/ml), Chaenomeles sinensis (2.17 µg/ml), Polygala tenuifolia (2.17 µg/ml), Paeonia japonica (2.17 µg/ml), Glycyrrhiza uralensis (2.17 µg/ml), Atractylodes japonica (2.17 µg/ml) and processed Aconitum carmichaeli (1.09 µg/ml). Concentration 2 [mecasin (50 µg/ml)]: Curcuma longa (8.7 µg/ml), Salvia miltiorrhiza (8.7 µg/ml), Gastrodia elata (8.7 µg/ml), Chaenomeles sinensis (4.35 µg/ml), Polygala tenuifolia (4.35 µg/ml), Paeonia japonica (4.35 µg/ml), Glycyrrhiza uralensis (4.35 µg/ml), Atractylodes japonica (4.35 µg/ml) and processed Aconitum carmichaeli (2.17 µg/ml). Concentration 3 [mecasin (100 µg/ml)]: Curcuma longa (17.4 µg/ml), Salvia miltiorrhiza (17.4 µg/ml), Gastrodia elata (17.4 µg/ml), Chaenomeles sinensis (8.7 µg/ml), Polygala tenuifolia (8.7 µg/ml), Paeonia japonica (8.7 µg/ml), Glycyrrhiza uralensis (8.7 µg/ml), Atractylodes japonica (8.7 µg/ml) and processed Aconitum carmichaeli (4.35 µg/ml). Concentration 4 [mecasin (200 µg/ml)]: Curcuma longa (34.8 µg/ml), Salvia miltiorrhiza (34.8 µg/ml), Gastrodia elata (34.8 µg/ml), Chaenomeles sinensis (17.4 µg/ml), Polygala tenuifolia (17.4 µg/ml), Paeonia japonica (17.4 µg/ml), Glycyrrhiza uralensis (17.4 µg/ml), Atractylodes japonica (17.4 µg/ml) and processed Aconitum carmichaeli (8.7 µg/ml).

Comparison of nitrite production by mecasin and its constituents at the same concentration

BV2 microglia were cultured for 12 h. After 12 h, cells were pre-treated with each test sample at the indicated concentration for 3 h and then stimulated with LPS for 24 h. Next, the concentration-dependent nitrite reduction effect of mecasin was compared with that of each constituent at the same concentration. The results indicated that C. longa, P. tenuifolia and G. uralensis had similar inhibitory effects on nitrite production, while S. miltiorrhiza had a relatively weak inhibitory effect on nitrite production. However, the remaining five individual constituents had no significant effect on nitrite reduction Fig. 7, Fig. 8, Fig. 9).

Figure 7

Inhibitory effects on mecasin, Curcuma longa, Salvia miltiorrhiza and Gastrodia elata at the same concentration on nitrite formation. Cells were pretreated with each sample at indicated concentrations for 3 h and stimulated with LPS at 1 µg/ml for 24 h. The nitrite concentration was determined as described in the nitrate assay paragraph of the Materials and methods. Values are expressed as the mean ± standard deviation of three independent experiments. ***P<0.001 vs. LPS group. The control is the untreated group. LPS, lipopolysaccharide.

Figure 8

Inhibitory effects of mecasin, Chanomeles sinensis, Polygala tenuifolia and Paeonia japonica at the same concentration on nitrite formation. Cells were pretreated with each test sample at indicated concentrations for 3 h and stimulated with LPS at 1 µg/ml for 24 h. The nitrite concentration was determined as described in the nitrate assay paragraph of the Materials and methods. Values are expressed as the mean ± standard deviation of three independent experiments. ***P<0.001 vs. LPS group. The control is the untreated group. LPS, lipopolysaccharide.

Figure 9

Inhibitory effects of mecasin, Glycyrrhiza uralensis, Atractylodes japonica and processed Aconitum carmichaeli at the same concentration on nitrite formation. Cells were pretreated with each test sample at the indicated concentrations for 3 h and stimulated with LPS at 1 µg/ml for 24 h. The nitrite concentration was determined as described in the nitrate assay paragraph of the Materials and methods. Values are expressed as the mean ± standard deviation of three independent experiments. ***P<0.001 vs. LPS group. The control is the untreated group. LPS, lipopolysaccharide.

Comparison of inhibitory effects of mecasin and its constituents on iNOS and COX-2 expression

It is well known that iNOS and COX-2 are responsible for the production of nitrite in LPS-induced microglia cells. Thus, it was examined whether the mecasin exerted its inhibitory effect on LPS-induced nitrite production through regulating iNOS and COX-2 expression by using western blot analysis. BV2 microglia were pre-treated with each sample at the indicated concentration for 3 h and then stimulated with LPS at 1 µg/ml for 24 h. As presented in Fig. 10, pre-treatment with mecasin or certain constituents thereof suppressed the expression of iNOS and COX-2 in a pattern similar to the inhibition rate of nitrite production.

Figure 10

Comparison of the inhibitory effects of mecasin and its constituents on the expression of iNOS and COX-2. Cells were pretreated with test samples at the indicated concentrations for 3 h and stimulated with LPS at 1 µg/ml for 24 h. Western blot analysis was performed as described in the western blotting section of the Materials and methods section. Representative blots from three independent experiments are presented. (A) Blots of iNOS and β-actin. (B) Blots of COX-2 and β-actin. Band intensities were normalized to β-actin. Values are expressed as the mean ± standard deviation. *P<0.05 and **P<0.01 vs. the LPS-treated control. iNOS, inducible nitrite oxide synthase; COX, cyclooxygenase; LPS, lipopolysaccharide.

Discussion

BV2 microglia are main immune effector cells in the brain. They have a major role in the pathogenesis of a wide range of chronic neuroinflammation and neurodegenerative diseases. A general feature of BV2 microglia in the inflammation of the central nervous system is the long-term activation of BV2 microglia and consequently increased inflammatory expansion, leading to increased release of inflammatory mediators. Therefore, BV2 microglia have a crucial role in the development of neuroinflammation and neurodegenerative diseases. BV2 microglia are known to secrete NO, tumor necrosis factor-α (TNF-α), IL-1β and other active substances involved in the pathogenesis of nervous system diseases (16,17). The expression of NOS is significantly increased in lesions of nervous system diseases. NOS is known to promote the production of NO. NO is able to form a strong oxidant that causes tissue oxidative damage after a series of reactions (18). TNF-α and IL-1β are strong pro-inflammatory factors that may increase the release of NO and aggravate inflammatory response and neuronal damage (19). Therefore, in the present study, BV2 microglia were chosen as an in vitro cell model. NO acts as a highly reactive free radical in the body. It is both a second messenger and a neurotransmitter. It is also an effector molecule that is widely used in the body. It has various physiological effects, such as relaxing vascular smooth muscle, inhibiting platelet aggregation, regulating cerebral blood flow, mediating cytotoxic effects and regulating the immune system. NO itself has a short half-life. NO in the blood is mainly produced by vascular endothelial cells, vascular smooth muscle cells, platelets and macrophages in the form of nitrite and nitrate. According to the principle that NO will form nitrite when it is dissolved in water, the content of NO was indirectly reflected by the nitrite content measured in the present study (19,20).

A previous study by our group have suggested that mecasin has anti-inflammatory and anti-oxidant effects (10). Jakyak-Gamcho-tang, a prescription that is the origin of mecasin, has been used mainly for alleviating pain, muscle spasms and cold syndrome due to blood deficiency for centuries in traditional oriental medicine (21). A previous study has indicated that mecasin is able to reduce the release of NO in activated microglial cells (10). However, the role of each ingredient regarding the total effect of mecasin has remained elusive. The results of the present study suggested that constituents of mecasin have synergistic anti-neuroinflammatory effects.

First, the concentration of individual ingredients was set based on mecasin concentrations of 25, 50, 100 and 200 µg/ml. Next, the toxicities of mecasin and its nine individual medicinal herb constituents were measured using an MTT assay. LPS-stimulated BV2 cells were selected as an experimental model to study effects of mecasin and its constituents on the release of inflammatory products. The results indicated that mecasin had the most potent effect. Among the single herbs, C. longa, P. tenuifolia and P. japonica also exhibited marked effects. Joseph et al (22) suggested that C. longa may act as a pro-drug, as its metabolite has anti-inflammatory activity. The metabolite produced by the oxidation of curcumin derived from C. longa is able to bind to NF-κB in a covalent bond, thereby further suppressing inflammatory reactions (22). Mecasin demonstrated a higher inhibitory effect on nitrite generation than its nine medicinal herb constituents. Next, we also checked that the effect of mecasin and its constituents (nine individual medicinal herbs) on iNOS and COX-2 expression was assessed. As presented in Fig. 10, mecasin and C. longa demonstrated the most prominent inhibitory effects. Furthermore, mecasin demonstrated higher inhibitory effects compared with C. longa. The results suggested that treatment with mecasin inhibited the protein expression of iNOS and COX-2 to a greater extent than its nine herbal constituents separately. These results demonstrated that the most potent inhibitor of nitrite production and iNOS and COX-2 expression was mecasin, probably due to synergistic effects of its herbal medicinal constituents.

The effects of mecasin and its constituents on LPS-stimulated nitrite production and expression levels of iNOS and COX-2 on BV2 microglia cells at the same concentration were examined. Mecasin is not a simple combination of nine herbs with pharmacological effects. The first experiment was performed to observe neuroinflammatory effects of mecasin and its constituents at corresponding concentrations. It was indicated that mecasin (mixture of 9 components) had a higher effect than its individual herbal constituents. The second experiment was performed to observe their neuroinflammatory effects at the same concentration. The results suggested that three single individual herbal constituents had similar effects to those of mecasin. However, these three constituents exhibited higher cytotoxicity than mecasin at the same concentration. This result indicated that synergistic effects of constituents of mecasin may increase the effectiveness and safety of mecasin, indicating that mecasin has potential for treating neuroinflammation. To draw any reliable conclusions regarding the potential value of mecasin in neurological diseases, the results should be reperformed at least in another microglial cell line such as HMC3. Therefore, in a follow-up study, other microglial cells such as HMC3 cells will be used.

Finally, Chinese medicine is well known for reducing side effects and enhancing the efficacy of several drugs (23,24). In certain studies, some of the results regarding the lowering of highly toxic drug side effects and the enhancing of drug efficacy have been confirmed (23,24). Mecasin is a new combinational drug. However, a detailed mechanistic study on the synergistic effect of mecasin is required in future research.

Acknowledgements

Not applicable.

Funding

Funding: This research was supported by a grant from the Jeonbuk Research & Development Program funded by Jeonbuk province (grant no. RA202006-24-C4).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

TW and WK designed the experiments. DSL, JYS, DC and SK performed the nitrite and MTT assays. TW and WK drafted the manuscript or revised it critically for important intellectual content. DSL and SK gave final approval of the version to be published. All the authors verified and approved the final version of the manuscript. All the authors checked and approved the authenticity of the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Yoon HM, Jang KJ, Han MS, Jeong JW, Kim GY, Lee JH and Choi YH: Ganoderma lucidum ethanol extract inhibits the inflammatory response by suppressing the NF-κB and toll-like receptor pathways in lipopolysaccharide-stimulated BV2 microglial cells. Exp Ther Med. 5:957–963. 2013.PubMed/NCBI View Article : Google Scholar

2 

Amor S, Peferoen LAN, Vogel DYS, Breur M, van der Valk P, Baker D and van Noort JM: Inflammation in neurodegenerative diseases-an update. Immunology. 142:151–166. 2014.PubMed/NCBI View Article : Google Scholar

3 

Griffiths MR, Gasque P and Neal JW: The multiple roles of the innate immune system in the regulation of apopyosis and inflammation in the brain. J Neuropathol Exp Neurol. 68:217–226. 2009.PubMed/NCBI View Article : Google Scholar

4 

Hernagomez M, Carrillo-Salinas FJ, Mevha M, Correa F, Mestre L, Loría F, Feliú A, Docagne F and Guaza C: Brain innate immunity in the regulation of neuroinflammation: Therapeutic strategies by modulating CD200-CD200R interaction involve the cannabionoid system. Curr Pharm Des. 20:4707–4722. 2014.PubMed/NCBI View Article : Google Scholar

5 

Kim DH: Effect of Gamijakyakgamchobuja-tang on neuropathic pain in rats. Korean; Jeollabuk-do, Wonkwang Univ, 2015.

6 

Lee DS, Ko W, Song BK, Son I, Kim DW, Kang DG, Lee HS, Oh H, Jang JH, Kim YC and Kim S: The herbal extract KCHO-1 exerts a neuroprotective effect by ameliorating oxidative stress via heme oxygenase-1 upregulation. Mol Med Rep. 13:4911–4919. 2016.PubMed/NCBI View Article : Google Scholar

7 

Yu JW: Study on the ingredient of Jakyakgamchotang. Jeollabuk-do. Wonkwang Univ. Korean, 2010.

8 

Kim BW: Anti-inflammatory effect of Jakyakgamcho-tang. J Int Korean Med. 31:365–371. 2010.PubMed/NCBI View Article : Google Scholar

9 

Lee JM, Hong SY and Oh MS: Effects of Jakyakkamchobuja-tang on Papain-induced osteoarthritis in mice. J Korean Med. 34:116–135. 2013.

10 

Lee DS, Ko W, Yoon CS, Kim DC, Yun J, Lee JK, Jun KY, Son I, Kim DW, Song BK, et al: KCHO-1, a novel anti-neuroinflammatory agent, inhibits Lipopolysaccharide induced neuroinflammatory responses through Nrf2-mediated heme oxygenase-1 expression in mouse BV2 microglia cells. Evid Based Complement Alternat Med. 2014(357154)2014.PubMed/NCBI View Article : Google Scholar

11 

Cha E, Lee J, Lee S, Park M, Song I, Son I, Song BK, Kim D, Lee J and Kim S: A 4-week repeated dose oral toxicity study of Mecasin in Sprague-Dawley rats to determine the appropriate doses for a 13-week, repeated toxicity test. J Pharmacopuncture. 18:45–50. 2015.PubMed/NCBI View Article : Google Scholar

12 

Jeong H, Lee J, Cha E, Park M, Son I, Song B and Kim S: A study on the oral toxicity of mecasin in rats. J Pharmacopuncture. 17:61–65. 2014.PubMed/NCBI View Article : Google Scholar

13 

Cha E, Jeong H, Lee J, Lee S, Park M and Kim S: A study on single dose toxicity of Mecasin pharmacopuncture injection in muscle. J Korean Med. 36:36–42. 2015.

14 

Lee SJ, Jeong HH, Lee JC, Cha EH, Park MY and Song BG: A study on single dose toxicity of intravenous injection of Mecasin herbal acupuncture. J Korean Acupunct Moxibustion Med. 33:1–7. 2016.

15 

Kook MG, Choi SW, Seo Y, Kim DW, Song BK, Son I, Kim S and Kang KS: KCHO-1, a novel herbal anti-inflammatory compound, attenuates oxidative stress in an animal model of amyotrophic lateral sclerosis. J Vet Sci. 18:487–497. 2017.PubMed/NCBI View Article : Google Scholar

16 

Liu HY, Chen CY and Hsueh YP: Innate immune responses regulate morphogenesis and degeneration: Roles of Toll-like receptors and Sarml in neurons. Neurosci Bull. 30:645–654. 2014.PubMed/NCBI View Article : Google Scholar

17 

van Ham TJ, Brady CA, Kalicharan RD, Oosterhof N, Kuipers J, Veenstra-Algra A, Sjollema KA, Peterson RT, Kampinga HH and Giepmans BNG: Intravital correlated microscopy reveals differential macrophage and microgial dynamics during resolution of neuroinflammation. Dis Model Mech. 7:857–869. 2014.PubMed/NCBI View Article : Google Scholar

18 

Broholm H, Andersen B, Wanscher B, Frederiksen JL, Rubin I, Pakkenberg B, Larsson HB and Lauritzen M: Nitric oxide synthase expression and enzymatic activity in multiple Sclerosis. Acta Neural Scand. 109:261–269. 2004.PubMed/NCBI View Article : Google Scholar

19 

Baud V and Karin M: Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11:372–377. 2001.PubMed/NCBI View Article : Google Scholar

20 

Braddock M and Quinn A: Targeting IL-1 in inflammatory disease: New opportunities for therapeutic intervention. Nat Rev Drug Discov. 3:330–339. 2004.PubMed/NCBI View Article : Google Scholar

21 

Guo L, Cho SY, Kang SS, Lee SH, Baek HY and Kim YS: Orthogonal array design for optimizing extraction efficiency of active constituents from Jakyak-Gamcho Decoction, the complex formula of herbal medicines, Paeoniae Radix and Glycyrrhizae Radix. J Ethnopharmacol. 113:306–311. 2007.PubMed/NCBI View Article : Google Scholar

22 

Joseph AI, Edwards RL, Luis PB, Presley SH, Porter NA and Schneider C: Stability and anti-inflammatory activity of the reduction-resistant curcumin analog, 2,6-dimethyl curcumin. Org Biomol Chem. 16:3273–3281. 2018.PubMed/NCBI View Article : Google Scholar

23 

Liu J, Liu J, Shen F, Qin Z, Jiang M, Zhu J, Wang Z, Zhou J, Fu Y, Chen X, et al: Systems pharmacology analysis of synergy of TCM: An example using saffron formula. Sci Rep. 8(380)2018.PubMed/NCBI View Article : Google Scholar

24 

Bhuyan DJ, Perera S, Kaur K, Alsherbiny MA, Low M, Seto SW, Li CG and Zhou X: Synergistic Effects of Chinese Herbal Medicine and Biological Networks. In: Approaching Complex Diseases. Bizzarri M (ed). Springer, Cham, pp393-436, 2020.

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Wang T, Ko W, Shin J, Choi D, Lee D and Kim S: Comparison of anti‑inflammatory effects of Mecasin and its constituents on lipopolysaccharide‑stimulated BV2 cells. Exp Ther Med 21: 591, 2021.
APA
Wang, T., Ko, W., Shin, J., Choi, D., Lee, D., & Kim, S. (2021). Comparison of anti‑inflammatory effects of Mecasin and its constituents on lipopolysaccharide‑stimulated BV2 cells. Experimental and Therapeutic Medicine, 21, 591. https://doi.org/10.3892/etm.2021.10023
MLA
Wang, T., Ko, W., Shin, J., Choi, D., Lee, D., Kim, S."Comparison of anti‑inflammatory effects of Mecasin and its constituents on lipopolysaccharide‑stimulated BV2 cells". Experimental and Therapeutic Medicine 21.6 (2021): 591.
Chicago
Wang, T., Ko, W., Shin, J., Choi, D., Lee, D., Kim, S."Comparison of anti‑inflammatory effects of Mecasin and its constituents on lipopolysaccharide‑stimulated BV2 cells". Experimental and Therapeutic Medicine 21, no. 6 (2021): 591. https://doi.org/10.3892/etm.2021.10023
Copy and paste a formatted citation
x
Spandidos Publications style
Wang T, Ko W, Shin J, Choi D, Lee D and Kim S: Comparison of anti‑inflammatory effects of Mecasin and its constituents on lipopolysaccharide‑stimulated BV2 cells. Exp Ther Med 21: 591, 2021.
APA
Wang, T., Ko, W., Shin, J., Choi, D., Lee, D., & Kim, S. (2021). Comparison of anti‑inflammatory effects of Mecasin and its constituents on lipopolysaccharide‑stimulated BV2 cells. Experimental and Therapeutic Medicine, 21, 591. https://doi.org/10.3892/etm.2021.10023
MLA
Wang, T., Ko, W., Shin, J., Choi, D., Lee, D., Kim, S."Comparison of anti‑inflammatory effects of Mecasin and its constituents on lipopolysaccharide‑stimulated BV2 cells". Experimental and Therapeutic Medicine 21.6 (2021): 591.
Chicago
Wang, T., Ko, W., Shin, J., Choi, D., Lee, D., Kim, S."Comparison of anti‑inflammatory effects of Mecasin and its constituents on lipopolysaccharide‑stimulated BV2 cells". Experimental and Therapeutic Medicine 21, no. 6 (2021): 591. https://doi.org/10.3892/etm.2021.10023
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team